1-甲基-3-苯基-1H-吡唑-4-甲醛 | 304477-40-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-3-苯基-1H-吡唑-4-甲醛
• 中文别名: 1-甲基-3-苯基吡唑-4-甲醛
• 英文名称: 1-methyl-3-phenyl-1H-pyrazole-4-carbaldehyde
• 英文别名: 1-Methyl-3-phenyl-pyrazol-4-carbaldehyd；1-methyl-3-phenylpyrazole-4-carbaldehyde
• CAS: 304477-40-5
• 化学式: C₁₁H₁₀N₂O
• mdl: MFCD04972643
• 分子量: 186.213
• InChiKey: WJSFPCDQTDLOPK-UHFFFAOYSA-N

物化性质

• 沸点：
  356.4±30.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S24/25
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

SDS

Name:	1-Methyl-3-phenyl-1h-pyrazole-4-carbaldehyde 97% Material Safety Data Sheet
Synonym:
CAS:	304477-40-5

Section 1 - Chemical Product MSDS Name:1-Methyl-3-phenyl-1h-pyrazole-4-carbaldehyde 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
304477-40-5	1-Methyl-3-phenyl-1H-pyrazole-4-carbal	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 304477-40-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 105 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H10N2O
Molecular Weight: 186.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 304477-40-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-3-phenyl-1H-pyrazole-4-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 304477-40-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 304477-40-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 304477-40-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-3-苯基-1H-吡唑-4-甲醛 在 四丁基硫酸氢铵 sodium hydroxide 、 potassium permanganate 作用下， 以 甲苯 为溶剂， 反应 1.67h， 生成 1-甲基-3-苯基-吡唑
  参考文献：
  名称：

  Brehme; Gruendemann; Schneider, Journal fur Praktische Chemie (Weinheim), 2000, vol. 342, # 7, p. 700 - 706

  摘要：

  DOI：
• 作为产物：
  描述：

  苯乙酮缩氨基脲 在 potassium carbonate 、 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 5.08h， 生成 1-甲基-3-苯基-1H-吡唑-4-甲醛
  参考文献：
  名称：

  含（硫代）氨基脲的某些吡唑衍生物的合成及生物评价作为双重抗炎抗菌剂

  摘要：

  背景：设计并合成了一系列含有（硫）氨基脲（4a-4h，5a-5l，6a-6f，7a-7c）的吡唑衍生物，以筛选双重炎症和抗菌活性。 方法：通过1 H NMR，13 C NMR和HRMS对产物进行表征。用体外LPS诱导的TNF-α模型和体内二甲苯诱导的耳水肿模型评估其抗炎活性。使用系列稀释法针对几种革兰氏阳性菌株，革兰氏阴性菌株和真菌菌株评估了它们的体外抗菌活性。 结果：生物测定表明，大多数化合物在浓度为20 µg / mL时均可显着抑制TNF-α的表达。化合物5i，6b和7b在50 mg / mL剂量下具有与参考药物地塞米松相当的体内抗炎活性。公斤。此外，几种化合物对不同菌株显示出抗菌活性，化合物5g和5h分别显示对肺炎链球菌CMCC 31968和金黄色葡萄球菌CMCC 25923的有效抑菌活性，MIC值为8 µg / mL。同时具有抗炎和抗微生物活性的化合物7b，应按原样或在衍生后进行研究。

  DOI：

  10.2174/1570180816666190325163117

文献信息

• [EN] CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME<br/>[FR] COMPOSÉS CARBAMATES ET LEUR PROCÉDÉ DE FABRICATION ET D'UTILISATION
  申请人：ABIDE THERAPEUTICS

  公开号：WO2013142307A1

  公开（公告）日：2013-09-26

  Provided herein are carbamate compounds which may be useful in the treatment of, for example, pain, solid tumors and/or obesity.

  本文提供的是可能在治疗疼痛、实体肿瘤和/或肥胖等方面有用的氨基甲酸酯化合物。
• Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders
  作者：Justin S. Cisar、Olivia D. Weber、Jason R. Clapper、Jacqueline L. Blankman、Cassandra L. Henry、Gabriel M. Simon、Jessica P. Alexander、Todd K. Jones、R. Alan B. Ezekowitz、Gary P. O’Neill、Cheryl A. Grice

  DOI：10.1021/acs.jmedchem.8b00951

  日期：2018.10.25

  of hexafluoroisopropyl carbamate-based irreversible inhibitors of MGLL, culminating in a highly potent, selective, and orally available, CNS-penetrant MGLL inhibitor, 28 (ABX-1431). Activity-based protein profiling experiments verify the exquisite selectivity of 28 for MGLL versus other members of the serine hydrolase class. In vivo, 28 inhibits MGLL activity in rodent brain (ED50 = 0.5-1.4 mg/kg)

  丝氨酸水解酶单酰基甘油脂酶（MGLL）将内源性大麻素受体激动剂2-花生四烯酰基甘油（2-AG）和其他单酰基甘油转化为脂肪酸和甘油。MGLL的遗传或药理失活导致中枢神经系统2-AG升高，花生四烯酸和类二十烷酸相应减少，从而产生抗伤害性，抗焦虑和抗神经炎作用，而没有引起直接大麻素受体激动剂的全部精神活性作用。在这里，我们报告了基于六氟异丙基氨基甲酸酯的MGLL不可逆抑制剂的优化，最终形成了一种高效，选择性和口服的CNS渗透性MGLL抑制剂28（ABX-1431）。基于活性的蛋白质谱分析实验证明了MGLL与丝氨酸水解酶类别的其他成员相比具有28的出色选择性。在体内，28在鼠福尔马林疼痛模型中抑制了啮齿动物大脑中的MGLL活性（ED50 = 0.5-1.4 mg / kg），增加了大脑2-AG的浓度，并抑制了疼痛行为。ABX-1431（28）目前正在人类临床试验中进行评估。
• Aza-enamines X:Formylation of Pyrazole-4-carbaldehydeHydrazones at the Hydrazonoazomethine C-Atom
  作者：R. Brehme、E. Gründemann、M. Schneider、R. Radeglia、G. Reck、B. Schulz

  DOI：10.1055/s-2003-40527

  日期：——

  1,3-Disubstituted 1H-pyrazole-4-carbaldehyde-N,N-di­methylhydrazones 1 reacted with the Vilsmeier-Haack reagent, corresponding to the aza-enamine concept, in an electrophilic substitution reaction at the azomethine C-atom yielding the 1,4,5-triaza-pentadienium salts 2. These were hydrolysed to give 2-hydrazono-2-(1H-pyrazole-4-yl)ethanals 3. The electrophilic attack did not take place at the vinylogous position 5′ of the pyrazoles.

  1,3-双取代的1H-吡唑-4-甲醛-N,N-二甲基脲1与Vilsmeier-Haack试剂反应，符合氮杂烯胺概念，通过在偶氮甲碱C原子上的亲电取代反应生成了1,4,5-三氮杂戊二烯盐2。这些产物经水解得到2-腙基-2-(1H-吡唑-4-基)乙醛3。亲电攻击并未发生在吡唑的乙烯相似位点5′上。
• [EN] CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME<br/>[FR] COMPOSÉS DE CARBAMATE ET LEUR PRÉPARATION ET UTILISATION
  申请人：ABIDE THERAPEUTICS

  公开号：WO2013103973A1

  公开（公告）日：2013-07-11

  This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compunds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.

  本公开提供了可能是MAGL和/或ABHD6的调节剂的化合物和组合物，以及它们作为药用剂的用途，它们的制备过程，以及包括所公开化合物作为至少一种活性剂的药物组合物。该公开还提供了一种治疗有需要的患者的方法，其中患者患有疼痛、实体肿瘤癌和/或肥胖等症状，包括给予公开的化合物或组合物。
• [EN] PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF<br/>[FR] COMPOSÉS DE PYRROLO-PYRROLE CARBAMATE ET COMPOSÉS ORGANIQUES ASSOCIÉS, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS MÉDICALES
  申请人：ABIDE THERAPEUTICS INC

  公开号：WO2015003002A1

  公开（公告）日：2015-01-08

  The invention provides pyrrolo-pyrrole carbamate and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., solid tumor cancer, obesity, Down's syndrome, Alzheimer's disease, or pain, in a patient. The octahydropyrrolo pyrrole carbamates could be derived from hexafluoroisopropanol, Ν,Ν-disuccinimide and such. The activity of carbamates in MAGL, FAAH, and ABHD6 assays are also described.

  这项发明提供了吡咯-吡咯氨基甲酸酯及相关有机化合物，含有这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物治疗患者的方法，例如固体肿瘤癌症、肥胖症、唐氏综合征、阿尔茨海默病或疼痛。八氢吡咯-吡咯氨基甲酸酯可以由六氟异丙醇、Ν,Ν-二琥珀酰亚胺等物质衍生而来。此外还描述了氨基甲酸酯在MAGL、FAAH和ABHD6测定中的活性。